Table 4 Clinical characteristics according to category of body mass index (BMI)
Variable | Low weight or eutrophic n = 274 (100%) | Overweight n = 295 (100%) | Obese n = 209 (100%) | Total n = 788 (100%) | p-value |
|---|---|---|---|---|---|
Female sex (n; %) | 236 (86.1) | 254 (86.1) | 185 (88.5) | 675 (85.6) | 0.467 |
Non-white race/color (n; %) | 103 (37.6) | 120 (40.7) | 83 (39.7) | 462 (58.6) | 0.554 |
Age (mean ± SD) | 53.5 ± 13.3 | 54.6 ± 12.1 | 56.6 ± 9.9 | 57.0 ± 12.0 | 0.037 |
Disease duration (mean ± SD) | 13.4 ± 9.6 | 12.9 ± 8.6 | 12.3 ± 8.3 | 12.9 ± 8.9 | 0.389 |
Diabetes mellitus (n; %) | 36 (13.1) | 44 (14.9) | 37 (17.7) | 117 (14.8) | 0.168 |
Systemic arterial hypertension (n; %) | 117 (42.7) | 128 (43.4) | 139 (66.5) | 384 (48.7) | < 0.001 |
Dyslipidemia (n; %) | 70 (25.5) | 98 (33.2) | 92 (44.0) | 260 (32.9) | < 0.001 |
Family history of CVD (n; %) | 41 (14.9) | 50 (16.9) | 37 (17.7) | 128 (16.2) | 0.379 |
Smoking (n; %) | 35 (12.8) | 36 (12.2) | 21 (10.0) | 92 (11.7) | 0.319 |
Use of methotrexate (n; %) | 189 (68.9) | 196 (66.4) | 137 (65.5) | 522 (66.2) | 0.558 |
Use of prednisone (n; %) | 162 (59.1) | 188 (63.7) | 131 (62.7) | 481 (61.0) | 0.342 |
Use of leflunomide (n; %) | 94 (34.3) | 104 (35.2) | 73 (34.9) | 271 (34.3) | 0.972 |
C-reactive protein (mean ± SD) | 18.7 ± 59.0 | 14.7 ± 36.2 | 31.0 ± 138.9 | 20.4 ± 82.3 | 0.137 |
Rheumatoid factor (n; %) | 187 (68.2) | 192 (65.1) | 144 (68.9) | 523 (66.4) | 0.762 |
DAS28 (mean ± SD) | 3.97 ± 1.58 | 4.06 ± 1.49 | 4.21 ± 1.52 | 4.07 ± 1.53 | 0.298 |